C3 AI Announces New Employee Inducement Grant

C3 AI ("C3.AI, Inc." or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced that it granted an equity award under its 2025 Inducement Plan (the "Inducement Plan") to Tom MacMitchell, the Company's Senior Vice President and General Counsel, who recently joined the Company.

Effective July 30, 2026, C3 AI's Compensation Committee of the Board of Directors approved a restricted stock unit award covering 826,901 shares of C3 AI's Class A common stock (the "RSU Award"). Such award was granted as a material inducement in accordance with the employment inducement award exemption under the NYSE Listed Company Manual Section 303A.08.

The RSU Award will vest over a five-year term in accordance with the following schedule: subject to continued service, 165,380 RSUs will vest on the date twelve months following the July 27, 2026, vesting commencement date, with the remaining RSUs vesting in equal quarterly installments thereafter until the award is fully vested. Further, the RSU Award is subject to double-trigger acceleration: if a corporate transaction or change in control of the Company occurs during his employment and, within 36 months thereafter, he resigns for constructive termination or is terminated other than for cause, death or disability, any unvested portion of the award will accelerate in full, subject to his satisfaction of certain severance conditions, including a release of claims.

The RSU Award is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the award.

About C3 AI

C3 AI is the Enterprise AI application software company. C3 AI delivers a family of fully integrated products including the C3 Agentic AI Platform, an end-to-end platform for developing, deploying, and operating enterprise AI applications, C3 AI applications, a portfolio of industry-specific SaaS enterprise AI applications that enable the digital transformation of organizations globally, and C3 Generative AI, a suite of domain-specific generative AI offerings for the enterprise.

C3 AI Public Relations
Axicom
Mindy Nelson
830-214-4823
pr@c3.ai

Investor Relations
ir@c3.ai

News Provided by Business Wire via QuoteMedia

AI
The Conversation (0)
Homerun Resources Inc. Amends Terms of Previously Announced Financing

Homerun Resources Inc. Amends Terms of Previously Announced Financing

Homerun Resources Inc. (TSXV: HMR,OTC:HMRFF) (OTCQB: HMRFF) ("Homerun" or the "Company") is pleased to announce a slight amendment to the terms of the convertible security funding agreement (the "CFSA") previously announced on July 8, 2026 (the "Initial News Release"). The Initial News Release... Keep Reading...
Nine Mile Metals Announces Certified Assays of 3.49% Cu-Eq over 24.55 meters  in DDH WD-26-09

Nine Mile Metals Announces Certified Assays of 3.49% Cu-Eq over 24.55 meters in DDH WD-26-09

Including 4.03% Cu-Eq over 16.50m and 5.22% Cu-Eq over 6.50m Nine Mile Metals Ltd. (CSE: NINE,OTC:VMSXF) (OTCID: VMSXF) (FSE: KQ9) (the "Company" or "Nine Mile") is pleased to announce certified assay results for DDH WD-26-09, at the Wedge Mine in the Bathurst Mining Camp, New Brunswick. 3.49%... Keep Reading...
AmeriTrust Announces Second Quarter 2026 Financial Results

AmeriTrust Announces Second Quarter 2026 Financial Results

Funded lease contract growth accelerated in Q2 2026, with an increase of 205% in the value of contracts financed over Q1AmeriTrust Financial Technologies Inc. (TSXV: AMT,OTC:AMTFF) (OTCQB: AMTFF) (FSE: 1ZV) ("AmeriTrust", "AMT" or the "Company"), a fintech platform focused on automotive finance,... Keep Reading...
Aitenders Technologies Receives Final Approval from CSE and Commences Trading

Aitenders Technologies Receives Final Approval from CSE and Commences Trading

Aitenders Technologies Inc. (CSE: BIDS) (“Aitenders” or the “Company“), the developer of an end-to-end AI-powered platform for tender response and contract management purpose built for complex construction and infrastructure projects, is pleased to announce that the Company has received final... Keep Reading...
Solvonis Therapeutics (LSE:SVNS)

SVN-015 Advances into Further NIDA-Funded Studies Following Encouraging Initial Screening

Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, is pleased to announce encouraging results from the initial in vitro cardiac ion-channel and broader... Keep Reading...

Interactive Chart

Latest Press Releases

Related News